Down-regulation of lipocalin 2 suppresses the growth of human lung adenocarcinoma through oxidative stress involving Nrf2/HO-1 signaling

Acta Biochimica Et Biophysica Sinica
Baoquan SongZhongchao Han

Abstract

Lipocalin 2 (LCN2), a multifunctional secretory protein known as neutrophil gelatinase-associated lipocalin (NGAL), is expressed in a variety of cancers. However, little is known about the biological functions of NGAL in the development of lung adenocarcinoma. In the present study, we primarily found that NGAL expression was up-regulated in human lung adenocarcinoma tissues. Additionally, depletion of NGAL expression decreased the ability of cell proliferation and induced cell apoptosis. Furthermore, with the addition of N-acetylcysteine, a scavenger of reactive oxygen species (ROS), it was found that NGAL depletion was sufficient to cause apoptosis of lung adenocarcinoma cells by generating ROS through the inhibition of the nuclear factor E2-related factor 2/heme oxygenase-1 anti-oxidant pathway. Finally, the effect of NGAL down-regulation on the growth of human lung adenocarcinoma was determined in BALB/c nude mice. These findings demonstrate that NGAL may be a potential therapy target for patients with lung adenocarcinoma.

References

Aug 26, 2003·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Alfons Lawen
Dec 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jack B CowlandNiels Borregaard
May 19, 2004·American Journal of Nephrology·Jaya MishraPrasad Devarajan
Aug 3, 2005·The Biochemical Journal·Zhimin TongJames P Kehrer
Jun 8, 2007·Breast Cancer Research and Treatment·Maret BauerAndreas Friedl
Mar 8, 2008·Pharmacological Reviews·Nader G Abraham, Attallah Kappas
Sep 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Alessio IannettiAntonio Leonardi
Feb 3, 2009·The Journal of Biological Chemistry·Truyen NguyenCecil B Pickett
Mar 3, 2009·The European Respiratory Journal·A McWilliamsT Sutedja
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Nov 12, 2009·Cell Stress & Chaperones·Parisa BahmaniMehryar Habibi Roudkenar
Oct 23, 2010·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kyeong-Ah Jung, Mi-Kyoung Kwak
Nov 15, 2012·The Journal of Clinical Endocrinology and Metabolism·Vincenzo VolpeFrancesco Pacifico
Dec 1, 2012·Archives of Pathology & Laboratory Medicine·Paul A Bunn
Apr 20, 2014·Oncotarget·Saverio CandidoMassimo Libra

❮ Previous
Next ❯

Citations

May 3, 2016·International Journal of Molecular Sciences·Sadaf SultanSilke Cameron
Apr 25, 2020·Frontiers in Oncology·Rikki A M BrownPeter J Leedman
Nov 14, 2019·Cell Reports·Lucie YammineMorgan Gallazzini
Apr 4, 2021·International Journal of Molecular Sciences·Marinela KrizanacAnastasia Asimakopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Courtney MunroCathy Quinlan
Clinical Chemistry and Laboratory Medicine : CCLM
Giuseppe Lippi, Mario Plebani
Clinical Chemistry and Laboratory Medicine : CCLM
Giuseppe Lippi, Mario Plebani
© 2021 Meta ULC. All rights reserved